Form 4: Zevra Therapeutics Insider Trades Common Stock
Statement of Changes in Beneficial Ownership
Rahsaan Thompson, Chief Legal & Compliance Officer at Zevra Therapeutics, Inc., reported a transaction involving the acquisition of 1,794 shares of common stock.
Summary
- Rahsaan Thompson, Chief Legal & Compliance Officer at Zevra Therapeutics, Inc., acquired 1,794 shares of common stock on May 11, 2026.
- The transaction was made under a Rule 10b5-1(c) trading plan adopted on January 8, 2026.
- Following this transaction, Thompson beneficially owns 48,125 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction executed under a pre-approved plan, with no immediate indication of positive or negative company performance.
Positives
- The transaction was executed under a pre-established 10b5-1(c) trading plan, indicating a planned and systematic approach to stock transactions rather than opportunistic trading.
- The acquisition of shares by a key executive can be interpreted as a positive signal of confidence in the company's future prospects.
Future Outlook
The filing itself does not contain forward-looking statements or guidance. The transaction occurred under a pre-defined plan.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by Zevra Therapeutics' Chief Legal & Compliance Officer is a common practice for executives to manage their stock holdings in a pre-determined manner, mitigating concerns about insider trading.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| 10b5-1 Trading Plan | Transaction executed under a written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 01-08-2026 | Enhances compliance with insider trading regulations by establishing a pre-determined trading strategy. |
Stakeholder Impact
- Shareholders: The transaction itself does not directly impact share price, but the adherence to a 10b5-1 plan can provide reassurance regarding executive compliance with trading regulations.
Key Dates
| Date | Description |
|---|---|
| 01-08-2026 | Adoption date of the referenced 10b5-1(c) plan. |
| 05/11/2026 | Transaction date for the acquisition of common stock. |
| 05/13/2026 | Date of filing for the Form 4 statement. |
Keywords
Form 4, Insider Trading, Zevra Therapeutics, Common Stock, 10b5-1 plan, Beneficial Ownership, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.